Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older at the time of signing consent forms.
- People who are willing and able to sign a consent form voluntarily and in writing.
- People who are able to understand the study and follow all of its requirements.
- People who have been diagnosed with, or are suspected to have, certain types of cancer, including (but not limited to): clear cell renal cell cancer, urothelial carcinoma, colorectal cancer, cervical cancer, ovarian cancer, head and neck cancer, hepatocellular carcinoma, cholangiocarcinoma, non-small cell lung cancer, small cell lung cancer, breast cancer, pancreatic cancer, endometrial cancer, or Von Hippel Lindau disease.
Who may not be able to join:
- People who have a serious non-cancer illness — such as a psychiatric condition, an infection, an autoimmune disorder, or a metabolic condition — that the trial doctor believes could interfere with the study or with the person's safety.
- People whose mental health or cognitive ability may make it difficult to give informed consent or follow the study's requirements.
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Meng Liu, Peking University First Hospital
Phone: +86 010-83575252
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Diagnostic Sensitivity and Specificity of 18F-T2 PET/CT in the Evaluation of CAIX Positive Solid Tumors; Incidence of Adverse Events [Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.